Congratulations go out to Laurent Laferrière, Olivier Bourbonnais, Christelle Luce and the whole team at Montreal based startup Ditch Labs on the closing of a $1.3 Million Seed investment round. The capital injection will allow the company to pursue preclinical studies, advance its global regulatory plan and further product and algorithm development.
Founded in 2019 Ditch Labs is a multidisciplinary team of entrepreneurs, engineers, physicians, psychologists and pharma experts developing an innovative approach to nicotine addiction treatment, addressing both physiological and psychological addiction concurrently.
Cigarette smoking is the leading cause of preventable death
Even with the certain knowledge of its dangers cigarette smoking is still the number one cause of preventable deaths worldwide. Responsible for myriad cancers of the lungs, pancreas, throat, mouth and others these cancer numbers are miniscule when compared to the deaths from heart disease and stroke caused by cigarettes.
The majority of cigarette smokers want to quit, but the nature of the addiction is such that the average quit success rate hovers around 7%, and for those that have successfully quit it takes on average more than ten attempts before succeeding. New solutions are required to address this public health scourge and cause of so much suffering.
Part of the problem is that current smoking cessation products seek to treat a very complex addiction with a one-size-fits-all approach. Ditch is the first solution to adapt its treatment in real-time, based on craving intensity and behavioral feedback.
Laurent Laferriere, Co-founder & CEO, Ditch Labs
How does the Ditch Labs smoking cessation solution work?
The Ditch Labs solution seeks to bring together artificial intelligence technology, and personalized nicotine replacement therapy. It represents a new paradigm of cessation support based on a dynamic, progressive and personalized program.
Ditch Labs offers a revolutionary smoking cessation solution by developing the DitchPen™, a patent-pending medical vaporizer that precisely doses the quantity of nicotine administered, in order to reduce it automatically in a gradual and personalized way. The medical device is paired with a mobile application that uses machine learning algorithms to learn, adapt and act as a behavioural assistant throughout the withdrawal process.
From Ditch Labs website
In our position at the intersection of medical technology, clinical research and patient-centric healthcare BML Technology has the privilege of working backstage with some of the most exciting digital health organizations in the world, and we are proud of the work we’ve done with Ditch Labs.
We love the dynamism, innovation and entrepreneurship manifested by the Ditch Labs founders and their team in pursuit of their vision, and we seek to add value by helping them to manage the complex stakeholder interactions necessary to get their digital health solutions to market and gain adoption.
Ditch Labs is one of many innovative startups in the Montreal Digital Health Ecosystem addressing some of healthcare’s greatest challenges. We sincerely wish them the best of success and hope this investment will contribute significantly to the accomplishment of their mission. And that mission is a noble one. It is the saving of human lives , the reduction of human suffering and the resolution of crippling addictions.
About BML Technology
BML Technology understands digital health. At the intersection of medical technology, clinical research and patient-centric healthcare BML drives the mainstream adoption of digital technology in healthcare. Offering a full range of services to the digital health ecosystem BML manages the complex stakeholder interactions necessary to get digital health solutions to market and gain adoption.
Stay Connected with BML Technology.
Connect with BML Technology on LinkedIn.
Connect with Ditch Labs on LinkedIn.
